These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37961860)

  • 1. Denosumab Induces Neoplastic Stromal Cell Apoptosis
    Chen X; Ye F; He H; Chen G; Chen Z; Ye E; He B; Yang Y; Zhang J
    Curr Cancer Drug Targets; 2024; 24(5):565-578. PubMed ID: 37961860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone.
    Lau CP; Huang L; Wong KC; Kumta SM
    Connect Tissue Res; 2013; 54(6):439-49. PubMed ID: 24060052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
    Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
    J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
    Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
    Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Norcantharidin modulates the miR-30a/Metadherin/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone.
    Chen F; Wang S; Wei Y; Wu J; Huang G; Chen J; Shi J; Xia J
    Biomed Pharmacother; 2018 Jul; 103():1092-1100. PubMed ID: 29710674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
    Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
    PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor Effects of Cyclolinopeptide on Giant-cell Tumor of the Bone.
    Taniguchi Y; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Higuchi T; Abe K; Yonezawa H; Araki Y; Morinaga S; Kamei J; Nugroho AE; Kaneda T; Morita H; Tsuchiya H
    Anticancer Res; 2019 Nov; 39(11):6145-6153. PubMed ID: 31704842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
    Shibuya I; Takami M; Miyamoto A; Karakawa A; Dezawa A; Nakamura S; Kamijo R
    Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
    Sørensen AL; Hansen RL; Jørgensen PH
    Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
    Ud Din N; Umer M; Park YK
    Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of RANKL Expression in Osteocyte-like Differentiated Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment.
    Noguchi T; Sakamoto A; Murotani Y; Murata K; Hirata M; Yamada Y; Toguchida J; Matsuda S
    J Histochem Cytochem; 2023 Mar; 71(3):131-138. PubMed ID: 36971322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab for the treatment of giant cell tumor of the bone.
    Brodowicz T; Hemetsberger M; Windhager R
    Future Oncol; 2015; 11(13):1881-94. PubMed ID: 26161925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone.
    Cowan RW; Singh G; Ghert M
    J Orthop Res; 2012 Jun; 30(6):877-84. PubMed ID: 22102368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of Osteosclerotic Change Following Treatment with an Antibody Against RANKL for Giant Cell Tumour of the Bone.
    Rosario M; Takeuchi A; Yamamoto N; Hayashi K; Miwa S; Higuchi T; Abe K; Taniguchi Y; Aiba H; Tanzawa Y; Murakami H; Tsuchiya H
    Anticancer Res; 2017 Feb; 37(2):749-754. PubMed ID: 28179326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
    Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
    Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets.
    Federman N; Brien EW; Narasimhan V; Dry SM; Sodhi M; Chawla SP
    Paediatr Drugs; 2014 Feb; 16(1):21-8. PubMed ID: 24114694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists.
    Tariq MU; Umer M; Khan Z; Saeed J; Siddiqui MA; Din NU
    Ann Diagn Pathol; 2020 Apr; 45():151479. PubMed ID: 32088577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical approach toward giant cell tumor of bone.
    van der Heijden L; Dijkstra PD; van de Sande MA; Kroep JR; Nout RA; van Rijswijk CS; Bovée JV; Hogendoorn PC; Gelderblom H
    Oncologist; 2014 May; 19(5):550-61. PubMed ID: 24718514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Translational Study of the Neoplastic Cells of Giant Cell Tumor of Bone Following Neoadjuvant Denosumab.
    Mak IW; Evaniew N; Popovic S; Tozer R; Ghert M
    J Bone Joint Surg Am; 2014 Aug; 96(15):e127. PubMed ID: 25100780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment.
    Toda Y; Kohashi K; Yamamoto H; Ishihara S; Ito Y; Susuki Y; Kawaguchi K; Kiyozawa D; Takamatsu D; Kinoshita I; Yamada Y; Maehara J; Kimura A; Tamiya S; Taguchi K; Matsunobu T; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
    Sci Rep; 2021 Jul; 11(1):14821. PubMed ID: 34285260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.